Table 2.
Treatment pattern among incident AD patients with monotherapy
| Index treatment | N | Ongoing or retreated with same index drug | Retreated with other AD drug | Discontinued | Switch to any AChEI | Switch to memantine | Adjunct therapy with memantine and AChEI |
|---|---|---|---|---|---|---|---|
| (a) Treatment pattern during the entire follow-up period | |||||||
| Donepezil | 3527 | 1881 (53.33%) | 231 (6.55%) | 774 (21.94%) | 107 (3.03%) | 130 (3.69%) | 395 (11.20%) |
| Rivastigmine | 761 | 345 (45.34%) | 68 (8.94%) | 170 (22.34%) | 50 (6.57%) | 32 (4.20%) | 83 (10.91%) |
| Galantamine | 98 | 39 (39.80%) | 15 (15.31%) | 27 (27.55%) | 8 (8.16%) | 1 (1.02%) | 7 (7.14%) |
| Memantine | 814 | 419 (51.47%) | 66 (8.11%) | 155 (19.04%) | 44 (5.41%) | 130 (15.97%) | |
| Any anti-dementia druga | 5200 | 2684 (51.62%) | 380 (7.31%) | 1126 (21.65%) | 615 (11.83%) | ||
| Any AChEIb | 4386 | 2265 (51.64%) | 314 (7.16%) | 971 (22.14%) | 485 (11.06%) | ||
| (b) Treatment pattern after the subsequent 1 year following initiation of AD treatment | |||||||
| Donepezil | 911 | 692 (75.96%) | 14 (1.54%) | 97 (10.65%) | 9 (0.99%) | 12 (1.32%) | 86 (9.44%) |
| Rivastigmine | 129 | 88 (68.22%) | 8 (6.20%) | 10 (7.75%) | 1 (0.78%) | 5 (3.88%) | 14 (10.85%) |
| Galantamine | 19 | 15 (78.95%) | 2 (10.53%) | 0 (0.00%) | 0 (0.00%) | 1 (5.26%) | 1 (5.26%) |
| Memantine | 193 | 151 (78.24%) | 3 (1.55%) | 21 (10.88%) | 6 (3.11%) | 12 (6.22%) | |
| Any anti-dementia druga | 1252 | 946 (75.56%) | 27 (2.16%) | 128 (10.22%) | 113 (9.03%) | ||
| Any AChEI** | 1059 | 795 (75.07%) | 24 (2.27%) | 107 (10.10%) | 101 (9.54%) | ||
AChEI Acetylcholinesterase inhibitors, AD Alzheimer’s disease
aAny anti-dementia: donepezil, rivastigmine, galantamine, and memantine
bAny AChEI: donepezil, rivastigmine, and galantamine